Company Update

RNS Number : 6686T

Hikma Pharmaceuticals Plc

01 October 2010

 



Hikma reiterates its guidance of at least 20% revenue growth for its US Generics business in 2010

London, 1 October 2010 - Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ DUBAI: HIK)("Hikma"), the fast growing multinational pharmaceutical group, notes recent press speculation that the United States Food and Drug Administration intends to take enforcement action against unapproved single-ingredient oral colchicine products and those companies that manufacture and sell them.

Hikma can confirm that it will comply with any FDA regulatory requirements related to the sale of colchicine, if such a notice is served.  Irrespective of the timing of such notification, Hikma is confident in reiterating its guidance of at least 20% revenue growth for its US Generics business for the full year 2010 and expects its core US Generics business will continue to perform well in 2011.

ENDS

Enquiries
Hikma Pharmaceuticals PLC	[phone]
Susan Ringdal, Investor Relations Director
Financial Dynamics
Ben Atwell	[phone]
Julia Phillips	[phone]
Matthew Cole

About Hikma

Hikma Pharmaceuticals PLC is a fast growing global pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2009, Hikma achieved revenues of  $637 million and profit attributable to shareholders of $78 million.  For news and other information, please visit www.hikma.com.

 

END

 

 

MSCLFFSVAVIIVII